Back to top

Agenus announces three-year survival data from Phase 1b BOT+BAL study

Agenus (AGEN) announced that three-year survival data from the Phase 1b C-800-01 study of botensilimab, an Fc-enhanced multifunctional anti-CTLA-4 ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Agenus Inc. (AGEN)